New Products

Premium

Bruker Daltonics this week launched the solariX, its next-generation hybrid Qq-FTMS instrument for proteomics, petroleomics, metabolomics, and small-molecule drug and metabolite MALDI imaging.

New innovations include improved broad-band mass resolving power delivering eight times more power over earlier platforms, sensitivity greater than 10 times over earlier platforms, and dynamic range. "These dramatic improvements help address today's most challenging top-down proteomics and complex mixture applications," the company said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.